Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions.

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

It is sold in two forms - Mounjaro and Zepbound - by United States (US ... Mounjaro is sold in pens containing 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg doses. Each pen contains a single-use dose and ...

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

SAN DIEGO – In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive ... ResMed’s research – it’s now tracking 1.2 million patients – also ...

For adults, about half think it’s a good thing, and about 2 in 10 think it’s a bad thing. The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, ...

The results, out after market close yesterday evening, came more than a month after the FDA approved Eli Lilly’s GLP-1 drug Zepbound (tirzepatide ... $345 million, or $2.34 per share, off ...

7-8 Approval was based on the response rates and duration of response found in results of the phase 2 eNRGy trial (ClinicalTrials.gov Identifier: NCT02912949). In December, FDA approved Imfinzi ...